HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY acquisition

This article was originally published in The Tan Sheet

Executive Summary

Supplement firm buys customer lists, URLs for Vitamins.com, WebRx.com from bankrupt HealthCentral for $2.8 mil. Acquisition includes customer list for L&H Vitamins mail-order operation. Deal was approved Dec. 6 in HealthCentral's bankruptcy proceedings and is expected to close later this month. Acquired operations had sales of approximately $15 mil. for the last 12 months and a combined customer list of roughly 1.8 mil. names, NBTY says. HealthCentral and its subsidiaries filed for Chapter 11 protection in October (1"The Tan Sheet" Oct. 15, In Brief)...

You may also be interested in...



Knox NutraJoint

NBTY's purchase of joint and nail health supplement line from Kraft Foods for approximately $4 mil. expected to close by end of December, firms announce Dec. 19. Purchase includes original NutraJoint and NutraJoint Plus Glucosamine, as well as Knox for Nails. Revenues of acquired products are expected to reach roughly $15 mil. in 2001. NBTY recently announced plans to purchase customer lists, URLs for Vitamins.com, WebRx.com from bankrupt HealthCentral (1"The Tan Sheet" Dec. 17, In Brief)...

HealthCentral

E-tailer and subsidiaries, including Vitamins.com and WebRx.com, file for Chapter 11 bankruptcy protection, firm announces Oct. 9. Company says it "intends to proceed with a sale of its assets...in an effort to maximize the value of the business for all of its stakeholders." In September, HealthCentral announced a 43% workforce reduction and saw its stock transferred to the NASDAQ Small Cap market (1"The Tan Sheet" Oct. 1, p. 13)

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel